PDCD1 and cancer: Despite advances in utilizing ICIs in cancer immunotherapy, predictive markers which are currently used, such as tumor mutational burden and PD-L1/PD-1 expression status, have limitations and encounter challenges in precisely and comprehensively identifying patients with a high likelihood of responding positively to immunotherapy [304].